Developing and commercializing novel cancer immunotherapies
Lion Biotechnologies is focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy licensed from the National Cancer Institute for the treatment of refractory metastatic melanoma. Tumor infiltrating lymphocytes (TILs) isolated from the patient’s tumor following resection are expanded in vitro away from the cancer’s immune-suppressing effects, and then these potent anti-tumor lymphocytes are infused back into the patient. Several former members of Acerta Pharma B.V. (sold to AstraZeneca for up to $7 billion in 2016) have been appointed key management roles at Lion.